Services

Strategic Scientific & Quality Advisory for Life Sciences Organizations

I work with life sciences companies at critical inflection points — where scientific ambition, quality expectations, and business decisions intersect. My role is to provide an independent, senior-level perspective that helps leadership teams and boards make confident, defensible decisions in complex and regulated environments.

Drawing on over 30 years of global experience — including formative work in Japan, where quality management principles are deeply embedded in organizational culture — I help organizations move beyond compliance and build a mature, practical understanding of Quality Management Systems (QMS) as a leadership and decision-making framework.

How I Support Organizations

1. Board & Executive Advisory

I advise boards, founders, and executive teams on scientific, quality, and translational strategy at moments when judgment matters more than execution.

Typical focus areas:

• Scientific and quality governance

• Risk awareness at the board level

• Strategic readiness for growth, partnerships, or investment

• Independent perspective on critical decisions
  
  

Format: advisory meetings, board sessions, executive discussions (virtual or in person)

2. Quality Systems as a Strategic Enabler

Many organizations approach QMS primarily as a compliance requirement. I help leadership teams reframe quality as a strategic system that supports credibility, scalability, and long-term value.

What this looks like in practice:

• Deep discussions of core QMS principles using real organizational cases

• Clarifying common misconceptions (e.g. leadership as a system-wide responsibility, not only

 a management function)

• Aligning quality systems with scientific strategy and organizational maturity
  
  

The goal is not documentation — it is shared understanding and better decisions.

3. Scientific, Preclinical & Translational Risk Advisory

I support leadership teams in identifying and addressing scientific and translational risks before they become regulatory, financial, or reputational liabilities.

Support includes:

• Strategic review of preclinical and translational assumptions

• Readiness assessments for the next development or funding stages

• Framing scientific complexity in decision-ready language for executives and investors
  
  

4. Strategic Reviews & Decision Support

For organizations facing high-stakes choices, I provide focused, time-bound strategic input.

Examples:

• Scientific or quality readiness reviews

• Portfolio or program decision support

• Investor or partner-facing risk clarification

These engagements are designed to bring clarity, not create additional operational burden.

How I Work

• Senior, independent, and objective

• Advisory, not operational execution

• Focused on judgment, clarity, and long-term impact

• Flexible formats: ad-hoc advisory, retainers, board or committee roles
  
  

I am most effective when engaged early enough to influence direction — not after problems have already materialized.

I also collaborate, when appropriate, with CROs, CDMOs, and specialized service providers as an independent scientific and quality advisor. My role is not to sell operational services, but to help ensure that scientific direction, quality expectations, and partner capabilities are realistically aligned at early and critical stages. 

Who I Work With

• Life sciences and biotech companies

• Diagnostics and regulated technology organizations

• Investors and boards seeking scientific and quality insight

• Early- and growth-stage companies navigating complexity and scale
  
  

Let’s Talk

If your organization is navigating growth, innovation, regulatory expectations, or strategic uncertainty, I welcome a conversation to explore whether my perspective would be valuable.

For advisory or board-related inquiries, you may contact me at anelia.atanassova@bioglobax.com